Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYH33 in PROS and PRVM
NCT06975618Phase 2Recruiting
- Sponsor
- Haihe
- Start
- Aug 2023
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of risovalisib mesylate in PIK3CA-related overgrowth spectrum (PROS) and PIK3CA-related vascular malformations (4 cohorts), sponsored by Haihe. Primary endpoints: Maximum Tolerated Dose and/or Recommended Phase II Dose at 27 weeks and Objective Response Rate at 24 weeks. Started Aug 2023; status: recruiting.
02
Drugs
risovalisib mesylate
03
Conditions
PIK3CA-related overgrowth spectrum (PROS)PIK3CA-related vascular malformations
Beyond the preview
Go deeper on NCT06975618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06975618.